TrialBritish journal of cancer2010

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.

J-F Rossi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.